http://www.fpnotebook.com/
YasminAka: Drosperinone
- See Also
- Indications
- Contraindications
- Renal insufficiency
- Hepatic insufficiency
- Adrenal Insufficiency
- Mechanism of Drosperinone
- Newer synthetic Progestin
- Lowest Androgenic Activity
- Marginal benefit over other low androgen OCPs
- Antimineralcorticoid effect (Related to Spironolactone)
- Only OCP Progestin with antimineralcorticoid activity
- Antiandrogenic activity similar to Progesterone
- Efficacy
- Similar to other Oral Contraceptives
- Formulations: Yasmin
- Ethinyl Estradiol 30 ug
- Drospirenone 3 mg (equivalent to 25 mg Spironolactone)
- Drug Interactions: Potassium retention effects
- Potassium sparing Diuretics (e.g. Spironolactone)
- ACE Inhibitors
- Angiotensin Receptor Blockers
- Aldosterone Antagonists
- Heparin
- Nonsteroidal Anti-inflammatory drugs
- Monitoring: Serum Potassium in first month
- Indicated if concurrent use of drugs listed above
- Adverse Effects
- See Oral Contraceptive
- Potassium retention (see above)
- May be associated with higher thromboembolism risk
- Advantages
- May be associated with less weight gain than other OCP
- As effective as other OCPs in Acne Vulgaris
- May be useful in Polycystic Ovary Disease
- Spironolactone used for associated Hirsutism
- References
Yasmin (C0939533) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) , Hormone (T125) |
| MSH | C035144 |
| English | Yasmin |
| Sources | MSH, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |